Atjaunināt sīkdatņu piekrišanu

E-grāmata: Probiotics in The Prevention and Management of Human Diseases: A Scientific Perspective

Edited by (Assistant Professor, C.G. Bhakta Institute of Biotechnology, Uka Tarsadia University, Gujarat, India), Edited by (Assistant Professor in Microbiology, C.G. ), Edited by , Edited by (Assistant Professor, C.G. Bhakta Institute of Biotechnology, Uka Tarsadia University)
  • Formāts: EPUB+DRM
  • Izdošanas datums: 02-Dec-2021
  • Izdevniecība: Academic Press Inc
  • Valoda: eng
  • ISBN-13: 9780128237342
  • Formāts - EPUB+DRM
  • Cena: 166,99 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: EPUB+DRM
  • Izdošanas datums: 02-Dec-2021
  • Izdevniecība: Academic Press Inc
  • Valoda: eng
  • ISBN-13: 9780128237342

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

Probiotics in The Prevention and Management of Human Diseases: A Scientific Perspective addresses the use of probiotics and their mechanistic aspects in diverse human diseases. In particular, the mechanistic aspects of how these probiotics are involved in mitigating disease symptoms (novel approaches and immune-mechanisms induced by Probiotics), clinical trials of certain probiotics, and animal model studies will be presented through this book. In addition, the book covers the role of probiotics in prevention and management aspects of crucial human diseases, including multidrug resistant infections, hospital acquired infections, allergic conditions, autoimmune diseases, metabolic disorders, gastrointestinal diseases, neurological disorders, and cancers.

Finally, the book addresses the use of probiotics as vaccine adjuvants and as a solution for nutritional health problems and describes the challenges of using probiotics in management of human disease conditions as well as their biosafety concerns. Intended for nutrition researchers, microbiologists, physiologists, and researchers in related disciplines as well as students studying these topics require a resource that addresses the specific role of probiotics in the prevention and management of human disease.

Recenzijas

"Overall, the book provides a comprehensive review of the role of probiotics in human disease. Additionally, it moves the conversation toward their use in prevention and cure. There are very limited existing textbooks like this on the market, aside from a recently published title, Probiotics for Human Nutrition in Health and Disease, de Souza et al. (Elsevier, 2022), making comparison difficult. I noted grammatical errors and inconsistencies across sections, likely because a different group of researchers authored each chapter. If readers are able to overlook these details, this book proves itself a useful guide to improve the understanding of the present and possible future applications of probiotics. " --© Doodys Review Service, 2021, Kristen Kimble, MS, RD, LDN, reviewer, expert opinion

List of contributors xi
About the editors xv
Foreword xvii
Preface xix
1 The concept of probiotics, prebiotics, postbiotics, synbiotics, nutribiotics, and pharmabiotics 1(12)
Archana Chaudhari
Mitesh Kumar Dwivedi
1.1 Introduction
1(1)
1.2 Probiotics
1(2)
1.3 Prebiotics
3(2)
1.4 Synbiotics
5(1)
1.5 Postbiotics
6(1)
1.6 Nutribiotics
7(1)
1.7 Pharmabiotics
7(2)
Acknowledgments
9(1)
References
9(4)
2 Food or pharma: the name does make a difference 13(28)
Magali Cordaillat-Simmons
Alice Rouanet
Bruno Pot
2.1 Introduction
13(1)
2.2 Probiotics: a substance or a product?
13(3)
2.3 The various regulatory statuses applicable to products containing "probiotics"
16(15)
2.4 Comparative summary
31(6)
2.5 Conclusion: the name does make a difference
37(1)
Conflict of interest
38(1)
Notice
38(1)
References
38(3)
3 The role of probiotics in maintaining immune homeostasis 41(18)
Velaphi C. Thipe
Shireen Mentor
Caroline S.A. Lima
Lucas F. Freitas
Ana C.M. Fonseca
Kamila M. Nogueira
Adriana S. Rodrigues
Jorge G.S. Batista
Aryel H. Ferreira
Ademar B. Lugao
3.1 Introduction
41(12)
3.2 Conlusion
53(1)
Acknowledgment
53(1)
References
53(6)
4 Effect of intestinal microbiome, antibiotics, and probiotics in the prevention and management of ulcerative colitis 59(34)
Ivan Kushkevych
Josef Jampilek
4.1 Introduction
59(2)
4.2 The role of intestinal microbiota in the development of bowel diseases
61(9)
4.3 General characteristics of drugs used in bowel diseases
70(4)
4.4 Modification of intestinal microbiome
74(7)
4.5 Conclusion
81(1)
Acknowledgments
81(1)
References
81(12)
5 Probiotics in the prevention and management of necrotizing enterocolitis 93(8)
Eleonora Seghesio
Charlotte De Geyter
Yvan Vandenplas
5.1 Introduction
93(1)
5.2 The microbiome, dysbiosis, and NEC
93(1)
5.3 Most relevant mechanisms of probiotic action in the preterm
94(1)
5.4 Probiotics and prevention of NEC
94(2)
5.5 Safety aspects of probiotics
96(1)
5.6 Conclusions and challenges for future research
96(1)
References
97(4)
6 Probiotics in the prevention and management of irritable bowel syndrome 101(6)
Elvira Ingrid Levy
Charlotte De Geyter
Bruno Hauser
Yvan Vandenplas
6.1 Introduction
101(1)
6.2 Probiotics in prevention and management of IBS
102(1)
6.3 Conclusion
103(1)
References
104(3)
7 Probiotics in the prevention and treatment of diarrhea! disease 107(10)
Aruna Jyothi Kora
7.1 Introduction
107(2)
7.2 Diarrhea! diseases
109(1)
7.3 Probiotics in prevention and treatment of diarrhea! diseases
109(4)
7.4 Mode of action of probiotics
113(1)
7.5 Conclusions
113(1)
Acknowledgment
114(1)
References
114(3)
8 Probiotics in the prevention and treatment of atopic skin diseases 117(12)
Archana Chaudhari
Ankit Bharti
Mitesh Kumar Dwivedi
8.1 Introduction
117(1)
8.2 Etiology and pathophysiology of atopic dermatitis
117(1)
8.3 Relationship between gut microbiota and atopic dermatitis
118(1)
8.4 Intervention of probiotics in atopic dermatitis
119(4)
8.5 Future perspectives of probiotics in prevention and treatment of AD
123(1)
8.6 Conclusion
124(1)
Acknowledgment
124(1)
References
124(5)
9 Probiotics for the treatment of other skin conditions (acne, psoriasis, seborrheic dermatitis, wounds, and skin cancer) 129(10)
Sophia Sangar
Michelle W. Cheng
Yang Yu
9.1 Acne vulgaris
129(1)
9.2 Psoriasis
130(1)
9.3 Seborrheic dermatitis
131(1)
9.4 Wound healing
132(1)
9.5 Skin cancer
133(1)
References
134(5)
10 Probiotics in the prevention and management of allergic diseases (asthma and allergic rhinitis) 139(8)
Lien Meirlaen
Elvira Ingrid Levy
Yvan Vandenplas
10.1 Introduction
139(1)
10.2 Prevention of asthma
140(1)
10.3 Probiotics for the treatment of asthma
141(1)
10.4 Probiotics for the prevention of allergic rhinitis
141(1)
10.5 Probiotics for the treatment of allergic rhinitis
142(1)
10.6 Conclusions
143(1)
Acknowledgment
143(1)
Funding
143(1)
Conflicts of interest
143(1)
References
143(4)
11 Prenatal and neonatal probiotic intake in pediatric allergy 147(14)
Youcef Shahali
Naheed Mojgani
Maryam Dadar
11.1 Introduction
147(1)
11.2 Safety of probiotics and prebiotics
148(1)
11.3 Probiotics, prebiotics, and immunity
149(1)
11.4 Microbiota and allergic disorders
150(1)
11.5 Mother's microbiome and child health
151(1)
11.6 Clinical studies
152(4)
11.7 Conclusions
156(1)
References
156(5)
12 Probiotics and prebiotics in the suppression of autoimmune diseases 161(26)
Prashant S. Giri
Firdosh Shah
Mitesh Kumar Dwivedi
12.1 Introduction
161(1)
12.2 Autoimmune diseases
162(1)
12.3 Relationship between gut microbiota and immune system
163(2)
12.4 Gut microbiota associated with autoimmune diseases
165(2)
12.5 Beneficial role of probiotics in the suppression of autoimmune diseases
167(11)
12.6 Future perspectives
178(1)
12.7 Conclusions
178(1)
Acknowledgments
179(1)
Conflict of interest
179(1)
References
179(8)
13 Probiotics and prebiotics in the prevention and management of human cancers (colon cancer, stomach cancer, breast cancer, and cervix cancer) 187(26)
Josef Jampilek
Katarina Kralova
Vladimir Bella
13.1 Introduction
187(4)
13.2 Probiotics and prebiotics in stomach cancer
191(2)
13.3 Probiotics and prebiotics in colon cancer
193(5)
13.4 Probiotics and prebiotics in breast cancer
198(2)
13.5 Probiotics and prebiotics in cervical cancer
200(2)
13.6 Conclusion
202(1)
Acknowledgment
203(1)
References
203(10)
14 Probiotics in mitigation of food allergies and lactose intolerance 213(10)
Bhuvan Shankar Vadala
Prasant Kumar
Mitesh Kumar Dwivedi
14.1 Introduction of probiotics and the gut microbiome
213(1)
14.2 Food allergies and lactose intolerance
213(1)
14.3 Lactose intolerance
214(1)
14.4 Role of probiotics in mitigation of food allergies and lactose intolerance
214(2)
14.5 Dietary management strategies
216(1)
14.6 Therapeutic applications
216(1)
14.7 Intake of probiotics
216(1)
14.8 Future prospective of probiotic in food allergies
217(1)
14.9 Conclusions
218(1)
References
218(5)
15 Probiotics in the prevention and treatment of nosocomial infections 223(14)
Julie Kalabalik-Hoganson
Malgorzata Slugocki
Elif Ozdener-Poyraz
15.1 Introduction
223(1)
15.2 Hospital-acquired pneumonia and ventilator-associated pneumonia
224(4)
15.3 Clostridium difficile infection
228(4)
15.4 Conclusion
232(1)
References
232(5)
16 Role of probiotics in urological health 237(6)
Santosh S. Waigankar
16.1 Introduction
237(1)
16.2 Vaginal microbiota
237(1)
16.3 Commensal microbial flora and preventing UTI
237(1)
16.4 Scope of the problem
238(1)
16.5 Urinary tract infection
238(1)
16.6 Bacterial vaginosis
238(1)
16.7 Yeast vaginitis
238(1)
16.8 Modes of administration of probiotics
239(1)
16.9 What does the evidence say?
240(1)
16.10 Conclusion
240(1)
References
240(3)
17 Role of probiotics in prevention and treatment of Candida vaginitis and Bacterial vaginosis 243(8)
Adekemi Titilayo Adesulu-Dahunsi
17.1 Introduction
243(1)
17.2 Healthy vaginal microflora and probiotic lactobacilli
244(1)
17.3 Vaginitis (vaginal infection)
244(1)
17.4 Probiotic roles in the prevention and treatment of vaginal infection
245(1)
17.5 Conclusion
246(1)
References
247(4)
18 Role of probiotics in the prevention and treatment of oral diseases 251(14)
Devang Bharatkumar Khambholja
Prasant Kumar
Rushikesh G. Joshi
Hiteshkumar V. Patel
18.1 Introduction
251(1)
18.2 Role of probiotics in prevention and treatment of dental caries
252(1)
18.3 Role of probiotics in the prevention and treatment of periodontal diseases
253(2)
18.4 Role of probiotics in the prevention and treatment of halitosis
255(4)
18.5 Conclusions
259(1)
References
259(6)
19 Role of probiotics in infections with multidrug-resistant organisms 265(16)
Basavaprabhu Haranahalli Nataraj
Rashmi Hogarehalli Mallappa
19.1 Introduction
265(1)
19.2 Probiotics
266(1)
19.3 General mechanisms of actions of probiotics against MDR bacteria
267(5)
19.4 Probiotics in organ-specific resistant infections
272(2)
19.5 Conclusion
274(1)
References
275(6)
20 Probiotics in the prevention and treatment of infections with Helicobacter pylori, Enterohemorrhagic Escherichia coli, and Rotavirus 281(24)
Nilanjana Das
Mangala Lakshmi Ragavan
Sanjeeb Kumar Mandal
20.1 Introduction
281(1)
20.2 Probiotics and their health implications
282(1)
20.3 Infections caused by Helicobacter pylori, enterohemorrhagic Escherichia coli, and rotavirus
283(2)
20.4 Helicobacter pylori
285(3)
20.5 Enterohemorrhagic Escherichia coli
288(3)
20.6 Rotavirus
291(4)
20.7 Conclusion and future perspectives
295(1)
References
296(9)
21 Role of probiotics in the management of fungal infections 305(16)
Archana Chaudhari
Ankit Bharti
Mitesh Kumar Dwivedi
21.1 Introduction
305(1)
21.2 Probiotics
305(1)
21.3 Probiotics in fungal diseases
306(8)
21.4 Future perspectives
314(1)
21.5 Conclusions
314(1)
Acknowledgment
315(1)
References
315(6)
22 Role of probiotics in the prevention and management of diabetes and obesity 321(16)
Rashmi Hogarehalli Mallappa
Chandrasekhar Balasubramaniam
Monica Rose Amarlapudi
Shweta Kelkar
Gbenga Adedeji Adewumi
Saurabh Kadyan
Diwas Pradhan
Sunita Grover
22.1 Introduction
321(1)
22.2 Pathophysiology and risk factors of diabetes mellitus and obesity
322(5)
22.3 Probiotics for the management of diabetes and obesity
327(5)
22.4 Conclusions
332(1)
References
332(5)
23 Probiotics in the prevention and management of cardiovascular diseases with focus on dyslipidemia 337(16)
Cintia Lacerda Ramos
Elizabethe Adriana Esteves
Rodrigo Pereira Prates
Lauane Gomes Moreno
Carina Sousa Santos
23.1 Introduction
337(1)
23.2 Probiotic bacteria
338(6)
23.3 Probiotic yeasts
344(1)
23.4 Conclusion
345(1)
References
345(8)
24 Gut-brain axis: role of probiotics in neurodevelopmental disorders including autism spectrum disorder 353(10)
Ranjith Kumar Manokaran
Sheffali Gulati
24.1 Introduction
353(1)
24.2 Colonization of the intestinal ecosystem in early life and its evolution
353(1)
24.3 Gut microbiota
354(1)
24.4 What are probiotics?
354(1)
24.5 Psychobiotics, prebiotics, and synbiotics
354(1)
24.6 Autism and probiotics
354(1)
24.7 ASD and GI disorders
354(1)
24.8 The gut-brain axis
355(1)
24.9 Neurodevelopmental disorders
356(1)
24.10 Is the gut microbiota of children with autism spectrum disorder different?
357(1)
24.11 Literature evidence in ASD
358(1)
24.12 Newer techniques involving microbiota
358(2)
24.13 ADHD
360(1)
24.14 Other neurodevelopmental disorders
360(1)
24.15 Future perspectives
360(1)
24.16 Conclusion
361(1)
References
361(2)
25 Probiotics in the prevention and control of foodborne diseases in humans 363(20)
Atef A. Hassan
Rasha M.H. Sayed-ElAhl
Ahmed M. El Hamaky
Noha H. Oraby
Mahmoud H. Barakat
25.1 Introduction
363(1)
25.2 Foodborne diseases
364(1)
25.3 Probiotics
364(3)
25.4 Antimicrobial potential of probiotics against foodborne pathogens
367(1)
25.5 Probiotics mechanisms of action in the control and prevention of foodborne pathogens
368(4)
25.6 Supplementation of probiotics in food materials
372(1)
25.7 Delivery system of probiotics
372(1)
25.8 The safety of probiotic therapy in host
372(1)
25.9 Health significance of probiotics in the prevention of foodborne diseases
373(1)
25.10 Conclusion and future perspectives
374(1)
Acknowledgment
374(1)
References
374(9)
26 Role of probiotics in the management of respiratory infections 383(14)
Cristina Mendez-Malagon
Alejandro Egea-Zorrilla
Pedro Perez-Ferrer
Julio Plaza-Diaz
26.1 Introduction
383(1)
26.2 Respiratory tract infections
384(1)
26.3 In search of new therapeutic strategies: microbiota and gut-lung axis
385(1)
26.4 Pulmonary microbiota in diseases
386(1)
26.5 History of probiotics
386(1)
26.6 Probiotic usage and safety
387(1)
26.7 Probiotic administration in respiratory infections
388(5)
26.8 Conclusion
393(1)
References
393(4)
27 The role of probiotics in nutritional health: probiotics as nutribiotics 397(20)
Maria Chavarri
Lucia Diez-Gutierrez
Izaskun Maranon
Maria del Carmen Villaran
Luis Javier R. Barron
27.1 Nutribiotics: ways to improve the nutritional status
397(3)
27.2 Nutritional health benefits of probiotics and postbiotics
400(5)
27.3 Encapsulation technology for the development of functional ingredients
405(3)
27.4 Current market of probiotics and future perspectives
408(1)
27.5 Conclusions
409(1)
References
409(8)
28 Role of immunobiotic lactic acid bacteria as vaccine adjuvants 417(14)
Maryam Dadar
Youcef Shahali
Naheed Mojgani
28.1 Introduction
417(1)
28.2 Vaccine adjuvants
417(1)
28.3 Probiotic lactic acid bacteria
418(7)
28.4 Conclusions
425(1)
References
425(6)
29 Probiotics: past, present, and future challenges 431(18)
Marieta Georgieva
Kaloyan Georgiev
Nadezhda Hvarchanova
29.1 Probiotics-the concept
431(1)
29.2 Probiotics-modern trends
432(3)
29.3 Viability of probiotic bacteria in the gastrointestinal tract and their secondary reproduction: probiotic concentration
435(2)
29.4 Dose of probiotics
437(1)
29.5 Safety of probiotic bacteria
437(1)
29.6 Health effects of probiotics
437(4)
29.7 Probiotics and metabolic syndrome
441(1)
29.8 Probiotics and urogenital infections
442(1)
29.9 Probiotics and immunity
442(1)
29.10 Probiotics and mental illness called Plus Ultra
443(1)
29.11 The next 45 years
443(1)
29.12 Summary
443(1)
29.13 Probiotics and Covid-19: data supporting the use of probiotics to prevent Covid-19
444(1)
29.14 Conclusion
445(1)
References
445(4)
30 Probiotics: health safety considerations 449(16)
Hemant Borase
Mitesh Kumar Dwivedi
Ramar Krishnamurthy
Satish Patil
30.1 Introduction
449(10)
30.2 Conclusions
459(1)
Acknowledgments
459(1)
Declaration of competing interest
459(1)
References
459(6)
31 Probiotics: current regulatory aspects of probiotics for use in different disease conditions 465(36)
Maja Sikic Pogaear
Duganka Mieetie-Turk
Sabina Fijan
31.1 Introduction
465(2)
31.2 Current regulation bodies that include probiotics
467(1)
31.3 Regulations for use of probiotics in gastrointestinal diseases
468(12)
31.4 Regulations for use of probiotics in diseases other than gastrointestinal diseases
480(8)
31.5 Conclusions
488(1)
References
489(12)
Index 501
Dr. Mitesh Kumar Dwivedi has completed PhD from Department of Biochemistry, The M. S. University of Baroda, Vadodara (2013); M.Sc. Microbiology from University of Mysore (2006) and B.Sc. Microbiology from Sardar Patel University (2004). Since 2014, he is serving as Assistant Professor at C. G. Bhakta Institute of Biotechnology, Uka Tarsadia University. He has published 42 research papers in reputed journals and written 5 book chapters. His research interests include exploring the immunological, genetic causes and therapeutics for autoimmune diseases such as Vitiligo, rheumatoid arthritis, thyroidism, etc. and use of probiotics in human health and diseases. Dr. N. Amaresan is an Assistant Professor at C.G. Bhakta Institute of Biotechnology, Uka Tarsadia University, Gujarat. He is a Microbiologist, having obtained his Ph.D., degree on endophytic PGP bacteria from Bharathidasan University, Tamil Nadu. Dr. N. Amaresan has over thirteen years of experience in teaching & research and made several original and novel discoveries in various allied fields of microbiology mainly plant-microbe interactions, bioremediation, plant pathology and others. For his original discoveries on agriculturally important microorganisms he has been awarded young scientist awards by Association of Microbiologists of India and National Academy of Biological Sciences. He also been awarded visiting scientist fellowship from National Academy of India to learn advanced techniques. He also deposited over 380 bacterial 16S rDNA and fungal ITS rDNA sequences in the Genbank (NCBI, EMBL & DDBJ) and also preserved over 150 microbial germplasm in various culture collection centres of India. Dr. A. Sankaranarayanan is working as an Assistant Professor in Microbiology, C.G. Bhakta Institute of Biotechnology, Uka Tarsadia University, Gujarat from 2015 onwards. Prior to his present position he served as an Assistant Professor & Head, Department of Microbiology, K.S.R. College of Arts & Science, Tiruchengode, Tamil Nadu from 2002-2015. He has experience in the fields of antimicrobial activity, antibacterial potential of nanoparticles and environmental microbiology. His current research focus is on antibacterial potential of herbal products against multi drug resistant microbial pathogens and pesticide / insecticide degradation by bacteria and fungi in freshwater ecosystem. Dr Helen Kemp completed her PhD in Microbiology at the University of Warwick and the Centre for Applied Microbiology and Research, Salisbury, in 1988. Since 1989, she has worked at the University of Sheffield as a Postdoctoral Research Fellow in the Department of Molecular Biology and Biotechnology and then in the Department of Oncology and Metabolism. She has a long-standing interest in the autoimmune and genetic aspects of the depigmenting disease vitiligo and has international collaborations on projects to profile autoantibody responses against melanocytes in melanoma, vitiligo and alopecia areata. She is also interested in characterizing autoimmune responses against the calcium-sensing receptor in patients with parathyroid autoimmunity. She has published more than 70 research papers and has contributed to books and review articles. She has been on the British Skin Foundation Grant Review Board and served as Section Editor for the British Journal of Dermatology.